Ignite Creation Date:
2025-12-25 @ 5:12 AM
Ignite Modification Date:
2025-12-26 @ 4:17 AM
Study NCT ID:
NCT05726227
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-24
First Post:
2023-02-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009765', 'term': 'Obesity'}], 'ancestors': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000591245', 'term': 'semaglutide'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 210}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2023-07-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2026-12-07', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-21', 'studyFirstSubmitDate': '2023-02-03', 'studyFirstSubmitQcDate': '2023-02-03', 'lastUpdatePostDateStruct': {'date': '2025-11-24', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-02-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-10-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Group Kids: Change in body mass index (BMI)', 'timeFrame': 'From baseline (week 0) to week 68', 'description': 'Measured in percentage (%)'}], 'secondaryOutcomes': [{'measure': 'Group Kids: Improvement in weight category', 'timeFrame': 'From baseline (week 0) to week 68', 'description': 'Measured as count of participants. Weight categories based on growth charts from Center for Disease Control (CDC).gov: Normal weight= BMI less than (\\<) 85th percentile, Overweight= BMI greater than or equal to (\\>=) 85th - \\<95th percentile, Obesity class I= BMI \\>=95th - \\<120% of the 95th percentile, Obesity class II= BMI \\>=120% - \\<140% of the 95th percentile, Obesity class III= BMI \\>=140% of the 95th percentile.'}, {'measure': 'Group Teens: Change in BMI', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in BMI', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Teens: Improvement in weight category', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as count of participants. Weight categories based on growth charts from CDC.gov: Normal weight= BMI less than (\\<) 85th percentile, Overweight= BMI greater than or equal to (\\>=) 85th - \\<95th percentile, Obesity class I= BMI \\>=95th - \\<120% of the 95th percentile, Obesity class II= BMI \\>=120% - \\<140% of the 95th percentile, Obesity class III= BMI \\>=140% of the 95th percentile.'}, {'measure': 'Group Kids and Group Teens: Improvement in weight category', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured as count of participants. Weight categories based on growth charts from CDC.gov: Normal weight= BMI less than (\\<) 85th percentile, Overweight= BMI greater than or equal to (\\>=) 85th - \\<95th percentile, Obesity class I= BMI \\>=95th - \\<120% of the 95th percentile, Obesity class II= BMI \\>=120% - \\<140% of the 95th percentile, Obesity class III= BMI \\>=140% of the 95th percentile.'}, {'measure': 'Group Kids and Group Teens: Change in body weight', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in percentage'}, {'measure': 'Group Kids and Group Teens: Change in body weight', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in percentage'}, {'measure': 'Group Kids and Group Teens: Change in body weight', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in kilograms (kg)'}, {'measure': 'Group Kids and Group Teens: Change in body weight', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in kilograms (kg)'}, {'measure': 'Group Kids and Group Teens: Change in BMI percentage of the 95th percentile', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in percentage points'}, {'measure': 'Group Kids and Group Teens: Change in BMI percentage of the 95th percentile', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in percentage points'}, {'measure': 'Group Kids and Group Teens: Change in BMI Standard deviation score (SDS)', 'timeFrame': 'From week 0 to week 68', 'description': "Measured as score on a scale. BMI SDS was calculated using the following formula: Z=\\[(value /M)\\^L - 1\\] / S\\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction."}, {'measure': 'Group Kids and Group Teens: Change in BMI SDS', 'timeFrame': 'From week 0 to week 104', 'description': "Measured as score in a scale. BMI SDS was calculated using the following formula: Z=\\[(value /M)\\^L - 1\\] / S\\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction."}, {'measure': 'Group Kids and Group Teens: Change in waist circumference', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in centimeters (cm)'}, {'measure': 'Group Kids and Group Teens: Change in waist circumference', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in centimeters (cm)'}, {'measure': 'Group Kids and Group Teens: Change in systolic blood pressure', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in millimeters of mercury (mmHg)'}, {'measure': 'Group Kids and Group Teens: Change in systolic blood pressure', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in millimeters of mercury (mmHg)'}, {'measure': 'Group Kids and Group Teens: Change in diastolic blood pressure', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in mmHg'}, {'measure': 'Group Kids and Group Teens: Change in diastolic blood pressure', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in mmHg'}, {'measure': 'Group Kids and Group Teens: Change in total cholesterol', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in total cholesterol', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in high density lipoprotein (HDL)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in high density lipoprotein (HDL)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in low density lipoprotein (LDL)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in low density lipoprotein (LDL)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in very low density lipoprotein (VLDL)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in very low density lipoprotein (VLDL)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in triglycerides', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in triglycerides', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in high sensitivity C-reactive protein (hs-CRP)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in high sensitivity C-reactive protein (hs-CRP)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in glycated haemoglobin (HbA1c)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in % point'}, {'measure': 'Group Kids and Group Teens: Change in glycated haemoglobin (HbA1c)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in % point'}, {'measure': 'Group Kids and Group Teens: Change in fasting plasma glucose', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in millimoles per liter (mmol/L)'}, {'measure': 'Group Kids and Group Teens: Change in fasting plasma glucose', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in millimoles per liter (mmol/L)'}, {'measure': 'Group Kids and Group Teens: Change in fasting plasma glucose', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in milligrams per deciliter (mg/dL)'}, {'measure': 'Group Kids and Group Teens: Change in fasting plasma glucose', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in milligrams per deciliter (mg/dL)'}, {'measure': 'Group Kids and Group Teens: Change in fasting insulin', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in fasting insulin', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Change in alanine transaminase (ALT)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in milliunits per liter (mU/L)'}, {'measure': 'Group Kids and Group Teens: Change in alanine transaminase (ALT)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in milliunits per liter (mU/L)'}, {'measure': 'Group Kids and Group Teens: Change in total fat mass, by Dual energy X-ray absorptiometry (DXA) relative to total body mass', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in % points'}, {'measure': 'Group Kids and Group Teens: Change in total fat mass, by Dual energy X-ray absorptiometry (DXA) relative to total body mass', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in % points'}, {'measure': 'Group Kids and Group Teens: Change in lean body mass, by DXA relative to total body mass', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in % points'}, {'measure': 'Group Kids and Group Teens: Change in lean body mass, by DXA relative to total body mass', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in % points'}, {'measure': 'Group Kids and Group Teens: Relative change in visceral fat mass by DXA', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Relative change in visceral fat mass by DXA', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in %'}, {'measure': 'Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 5% reduction of BMI (yes/no)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in count of participants'}, {'measure': 'Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 5% reduction of BMI (yes/no)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in count of participants'}, {'measure': 'Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 10% reduction of BMI (yes/no)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in count of participants'}, {'measure': 'Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 10% reduction of BMI (yes/no)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in count of participants'}, {'measure': 'Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 15% reduction of BMI (yes/no)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured in count of participants'}, {'measure': 'Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 15% reduction of BMI (yes/no)', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured in count of participants'}, {'measure': 'Group Kids and Group Teens: Number of treatment emergent adverse events (AEs)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as count of events'}, {'measure': 'Group Kids and Group Teens: Number of treatment emergent adverse events (AEs)', 'timeFrame': 'From week 0 to week 111', 'description': 'Measured as count of events'}, {'measure': 'Group Kids and Group Teens: Number of treatment emergent serious adverse events (SAEs)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as count of events'}, {'measure': 'Group Kids and Group Teens: Number of treatment emergent serious adverse events (SAEs)', 'timeFrame': 'From week 0 to week 111', 'description': 'Measured as count of events'}, {'measure': 'Group Kids and Group Teens: Change in pulse', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as beats per minute'}, {'measure': 'Group Kids and Group Teens: Change in pulse', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured as beats per minute'}, {'measure': 'Group Kids and Group Teens: Change in amylase', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as units per liter (U/L)'}, {'measure': 'Group Kids and Group Teens: Change in amylase', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured as units per liter (U/L)'}, {'measure': 'Group Kids and Group Teens: Change in lipase', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as U/L'}, {'measure': 'Group Kids and Group Teens: Change in lipase', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured as U/L'}, {'measure': 'Group Kids and Group Teens: Change in calcitonin', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as nanograms per liter (ng/L)'}, {'measure': 'Group Kids and Group Teens: Change in calcitonin', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured as nanograms per liter (ng/L)'}, {'measure': 'Group Kids and Group Teens: Change in bone mineral density, by DXA', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as grams per square centimeter (g/cm\\^2)'}, {'measure': 'Group Kids and Group Teens: Change in bone mineral density, by DXA', 'timeFrame': 'From week 0 to week 104', 'description': 'Measured as grams per square centimeter (g/cm\\^2)'}, {'measure': 'Group Kids and Group Teens: Number of treatment emergent hypoglycaemic episodes (for T2D only)', 'timeFrame': 'From week 0 to week 68', 'description': 'Measured as count of episodes'}, {'measure': 'Group Kids and Group Teens: Number of treatment emergent hypoglycaemic episodes (for T2D only)', 'timeFrame': 'From week 0 to week 111', 'description': 'Measured as count of episodes'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Obesity']}, 'descriptionModule': {'briefSummary': 'This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child\'s parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults.\n\nThe child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '18 Years', 'minimumAge': '6 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Informed consent of parent(s) or legally acceptable representative (LAR) of participant and child assent, as age-appropriate, obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. a) The parents or LAR of the child must sign and date the Informed Consent Form (according to local requirements) b) The child must sign and date the Child Assent Form or provide oral assent (according to local requirements)\n* Age at the time of signing informed consent. a)Group Kids: 6 to less than 12 years. b) Group Teens: 12 to less than 18 years and Tanner stage greater than 1\n* Body mass index (BMI), at screening and randomisation, corresponding to a) Group Kids: greater than or equal to 95th percentile. b) Group Teens: greater than or equal to 95th percentile or greater than or equal to 85th percentile with the presence of at least 1 weight-related comorbidity (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes mellitus (T2D)\n* History of at least one unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification programme (diet and exercise counselling) for at least 3 months\n* Body weight of greater than 45 kilogram (kg) at screening and randomisation\n* For participants with T2D at screening, the following additional criterion applies: glycated haemoglobin (HbA1c) less than or equal to 10.0 percent (86 millimoles per mole \\[mmol/mol\\]) as measured by central laboratory at screening\n\nExclusion Criteria:\n\n* Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening\n* Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: a) liposuction and/or abdominoplasty, if performed greater than 1 year prior to screening. b) adjustable gastric banding, if the band has been removed greater than 1 year prior to screening. c) intragastric balloon, if the balloon has been removed greater than 1 year prior to screening. d)duodenal-jejunal bypass liner (e.g., nonbarrier), if the sleeve has been removed greater than 1 year prior to screening\n* Type 1 diabetes mellitus or monogenic diabetes\n* Participants with endocrine, hypothalamic, or syndromic obesity\n* For participants with T2D at screening, the following additional key criterion applies: Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination'}, 'identificationModule': {'nctId': 'NCT05726227', 'acronym': 'STEP Young', 'briefTitle': 'A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novo Nordisk A/S'}, 'officialTitle': 'Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight', 'orgStudyIdInfo': {'id': 'NN9536-4512'}, 'secondaryIdInfos': [{'id': 'U1111-1266-3808', 'type': 'OTHER', 'domain': 'World Health Organization (WHO)'}, {'id': '2022-502922-41', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Group Kids', 'description': 'Participants in the age group 6 to less than (\\<) 12 years will receive once weekly subcutaneous (s.c.) injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.', 'interventionNames': ['Drug: Semaglutide', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Group Teens', 'description': 'Participants in the age group 12 to \\< 18 years will receive once weekly s.c. injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.', 'interventionNames': ['Drug: Semaglutide', 'Drug: Placebo']}], 'interventions': [{'name': 'Semaglutide', 'type': 'DRUG', 'description': 'Semaglutide will be administered subcutaneously once weekly.', 'armGroupLabels': ['Group Kids', 'Group Teens']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo will be administered subcutaneously once-weekly.', 'armGroupLabels': ['Group Kids', 'Group Teens']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92025', 'city': 'Escondido', 'state': 'California', 'country': 'United States', 'facility': 'Neighborhood Healthcare', 'geoPoint': {'lat': 33.11921, 'lon': -117.08642}}, {'zip': '06519', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Yale School of Medicine', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '31904', 'city': 'Columbus', 'state': 'Georgia', 'country': 'United States', 'facility': 'Columbus Research Foundation', 'geoPoint': {'lat': 32.46098, 'lon': -84.98771}}, {'zip': '30078', 'city': 'Snellville', 'state': 'Georgia', 'country': 'United States', 'facility': 'Eastside Bariatric and Gen Surg', 'geoPoint': {'lat': 33.85733, 'lon': -84.01991}}, {'zip': '83646', 'city': 'Meridian', 'state': 'Idaho', 'country': 'United States', 'facility': 'Solaris Clinical Research', 'geoPoint': {'lat': 43.61211, 'lon': -116.39151}}, {'zip': '70808', 'city': 'Baton Rouge', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Pennington Biom Res Ctr', 'geoPoint': {'lat': 30.44332, 'lon': -91.18747}}, {'zip': '71201', 'city': 'Monroe', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Clinical Trials of America LLC', 'geoPoint': {'lat': 32.50931, 'lon': -92.1193}}, {'zip': '71201', 'city': 'Monroe', 'state': 'Louisiana', 'country': 'United States', 'facility': 'IMA Clinical Research', 'geoPoint': {'lat': 32.50931, 'lon': -92.1193}}, {'zip': '21229', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'Barry J. Reiner, MD LLC', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital_Cary', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '55414', 'city': 'Minneapolis', 'state': 'Minnesota', 'country': 'United States', 'facility': 'University of Minnesota', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '39110', 'city': 'Madison', 'state': 'Mississippi', 'country': 'United States', 'facility': 'Mississippi Center for Advanced Medicine', 'geoPoint': {'lat': 32.46181, 'lon': -90.11536}}, {'zip': '39110', 'city': 'Madison', 'state': 'Mississippi', 'country': 'United States', 'facility': 'Mississippi CTR for ADV MED', 'geoPoint': {'lat': 32.46181, 'lon': -90.11536}}, {'zip': '14203', 'city': 'Buffalo', 'state': 'New York', 'country': 'United States', 'facility': 'UBMD Peds-Div of Endo/Diabetes', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}}, {'zip': '27610', 'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'WakeMed Childn Endo-Dbt_Raleig', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'zip': '58104', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Valley Weight Loss Clinic', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '43213', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Centricity Research - Ohio', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '15224', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'UPMC Child Hosp-Pittsburgh', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '37212', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Vanderbilt University Medical Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '37388', 'city': 'Tullahoma', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Tullahoma Pediatrics PLLC', 'geoPoint': {'lat': 35.36202, 'lon': -86.20943}}, {'zip': '78731', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Diabetes & Endocrinology', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '78207', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Univ Of Texas Hlth Science Cntr', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '23606', 'city': 'Newport News', 'state': 'Virginia', 'country': 'United States', 'facility': 'Health Res of Hampton Roads', 'geoPoint': {'lat': 36.98038, 'lon': -76.42975}}, {'zip': '54449', 'city': 'Marshfield', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Marshfield Clinic', 'geoPoint': {'lat': 44.66885, 'lon': -90.1718}}, {'zip': '6020', 'city': 'Innsbruck', 'country': 'Austria', 'facility': 'Universitätsklinik Kinder-Jugendheilkunde Innsbruck', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'zip': '5020', 'city': 'Salzburg', 'country': 'Austria', 'facility': 'Universitätsklinik für Kinder und Jugendheilkunde Haus E', 'geoPoint': {'lat': 47.79941, 'lon': 13.04399}}, {'zip': '1090', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'UZ Brussel', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '2650', 'city': 'Edegem', 'country': 'Belgium', 'facility': 'UZ Antwerpen - UZA - Kinderziekenhuis', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': '2650', 'city': 'Edegem', 'country': 'Belgium', 'facility': 'UZA - UZ Antwerpen - Kinderziekenhuis', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': '3000', 'city': 'Leuven', 'country': 'Belgium', 'facility': 'UZ Leuven - Kindergeneeskunde', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '9000', 'city': 'Aalborg', 'country': 'Denmark', 'facility': 'Aalborg Universitetshospital', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '8200', 'city': 'Aarhus', 'country': 'Denmark', 'facility': 'Aarhus Universitetshospital, Steno Diabetes Center Aarhus', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'zip': '4300', 'city': 'Holbæk', 'country': 'Denmark', 'facility': 'Holbæk Sygehus - Børne- og Ungeafdelingen', 'geoPoint': {'lat': 55.7175, 'lon': 11.71279}}, {'zip': '06120', 'city': 'Halle', 'country': 'Germany', 'facility': 'Universitätsklinikum Halle - Innere Medizin II', 'geoPoint': {'lat': 51.48158, 'lon': 11.97947}}, {'zip': '30173', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Hannoversche Kinderheilanstalt "Auf der Bult" - Diabeto-, Endokrino-, Gastroenterologie und Klinische Forschung', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '30173', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Kinder- und Jugendkrankenhaus', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Uniklinik Leipzig - Klinik und Poliklinik für Kinder- und Jugendmedizin', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Universitätsklinikum Leipzig, Klinik und Poliklinik für Kinder- und Jugendmedizin', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '89075', 'city': 'Ulm', 'country': 'Germany', 'facility': 'Uniklinik Ulm - Dt. Zentrum für Kinder- und Jugendgesundheit (DZKJ)', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '89075', 'city': 'Ulm', 'country': 'Germany', 'facility': 'Universitätsklinikum Ulm für Kinder- und Jugendmedizin', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '31096', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam MC - Department of Pediatrics A', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '49202', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Schneider MC - Endrocrinology and Diabetes', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '7033001', 'city': 'Ẕerifin', 'country': 'Israel', 'facility': 'Shamir MC - Pediatric and Adolescents Endocrinology unit', 'geoPoint': {'lat': 31.95731, 'lon': 34.84852}}, {'zip': '72190', 'city': 'Puebla City', 'country': 'Mexico', 'facility': 'Consultorio de Endocrinología y Pediatría', 'geoPoint': {'lat': 19.04778, 'lon': -98.20723}}, {'zip': '1500-650', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Hospital Da Luz S.A.', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '4050-342', 'city': 'Porto', 'country': 'Portugal', 'facility': 'Unidade Local de Saúde de Santo António, E.P.E', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'zip': '4100-180', 'city': 'Porto', 'country': 'Portugal', 'facility': 'Hospital CUF Porto S.A.', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'zip': '41650', 'city': 'Gothenburg', 'country': 'Sweden', 'facility': 'Drottning Silvias barnsjukhus', 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'zip': '30233', 'city': 'Halmstad', 'country': 'Sweden', 'facility': 'Hallands sjukhus Halmstad', 'geoPoint': {'lat': 56.67446, 'lon': 12.85676}}, {'zip': '75185', 'city': 'Uppsala', 'country': 'Sweden', 'facility': 'Akademiska sjukhuset Uppsala', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'zip': '75185', 'city': 'Uppsala', 'country': 'Sweden', 'facility': 'Uppsala universitetssjukhus', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'zip': 'B4 6NH', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': "Birmingham Children's Hospital", 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'BS2 8BJ', 'city': 'Bristol', 'country': 'United Kingdom', 'facility': 'University Hospitals Bristol & Weston NHS Foundation Trust', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'LS1 3EX', 'city': 'Leeds', 'country': 'United Kingdom', 'facility': "Leeds Children's Hospital", 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'L12 2AP', 'city': 'Liverpool', 'country': 'United Kingdom', 'facility': "Alder Hey Children's Hospital", 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'SO16 6YD', 'city': 'Southampton', 'country': 'United Kingdom', 'facility': 'Southampton General Hospital', 'geoPoint': {'lat': 50.90395, 'lon': -1.40428}}], 'overallOfficials': [{'name': 'Clinical Transparency dept. 2834', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novo Nordisk A/S'}]}, 'ipdSharingStatementModule': {'url': 'http://novonordisk-trials.com', 'ipdSharing': 'YES', 'description': 'According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}